Explore the invisible challenges life science startups face from R&D to commercialization — before they become costly mistakes.

In the early stages of a life science or biotech startup, most energy goes into proving the science, building a prototype, and raising funding. But many of the decisions that ultimately determine success happen quietly in the background — in documentation, regulatory strategy, material selection, sterilization processes, and compliance planning.

These “invisible” activities are often overlooked early on, only to become critical, and costly, later.

Join this Venture & Wine session to uncover the hidden risks and overlooked challenges startups face on their journey from R&D to commercialization.

🎤 Speakers

Pavla Frey – Senior Consultant (Freelance)

Søren Lyngsø Petersen – Medical Device Manager (Pharma4Ever)

Søren and Pavla bring extensive expertise in medical device quality, regulatory strategy, and compliance under frameworks such as ISO 13485 and EU MDR. They will uncover some of the invisible regulatory challenges startups often overlook early on, including and clinical evaluation requirements that later become critical for approval.

(Midas Pharma)
Knud Bæk Jensen – Business Development Manager

Dr. Danielle Leone Stumpf – Senior Director

Dr. Tilmann Grus – Project Manager

Knud, Danielle and Tilmann support biotech innovators from early development through manufacturing and commercialization. They will highlight hidden development and commercialization pitfalls that startups frequently underestimate, from GMP readiness and supply chain strategy to scaling manufacturing and navigating the transition from R&D to market.

🍷 Why Join?

• Understand the hidden factors that determine whether your innovation reaches the market.
• Gain practical insight from experts working hands-on with startups and companies.
• Network with founders, scientists, and industry professionals.
• Enjoy wine, pizza, and great conversation.

🎟️ Registration

Spots are limited — reserve your seat today!